Targeting connexin 43 in diabetic wound healing: Future perspectives

被引：22

作者：

Bajpai, S. ^{[1
]}

Shukla, V. K. ^{[2
]}

Tripathi, K. ^{[3
]}

Srikrishna, S. ^{[1
]}

Singh, R. K. ^{[1
]}

机构：

[1] Banaras Hindu Univ, Fac Sci, Dept Biochem, Varanasi 221005, Uttar Pradesh, India

[2] Banaras Hindu Univ, Inst Med Sci, Dept Surg, Varanasi 221005, Uttar Pradesh, India

[3] Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India

来源：

JOURNAL OF POSTGRADUATE MEDICINE | 2009年 / 55卷 / 02期

关键词：

Connexin-43; diabetes; diabetic wound; gap-junction proteins; JUNCTIONAL INTERCELLULAR COMMUNICATION; FIBROBLAST-GROWTH-FACTOR; FOOT ULCERS; MATRIX-METALLOPROTEINASES; GAP-JUNCTIONS; INDUCED APOPTOSIS; DOWN-REGULATION; GENE-TRANSFER; EXPRESSION; PROTEIN;

D O I：

10.4103/0022-3859.48786

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The unknown mechanisms of impaired tissue repair in diabetes mellitus are making this disease a serious clinical problem for the physicians worldwide. The lacuna in the knowledge of the etiology of diabetic wounds necessitates more focused research in order to develop new targeting tools with higher efficacy for their effective management. Gap-junction proteins, connexins, have shown some promising results in the process of diabetic wound healing. Till now the role of connexins has been implicated in peripheral neuropathy, deafness, skin disorders, cataract, germ cell development and treatment of cancer. Recent findings have revealed that gap junctions play a key role in normal as well as diabetic wound healing. The purpose of this review is to provide the information related to etiology, epidemiology, clinical presentation of diabetic wounds and to analyze the role of connexin 43 (Cx43) in the diabetic wound healing process. The current control strategies and the future research challenges have also been discussed briefly in this review.

引用

页码：143 / 149

页数：7

共 95 条

[1]

[Anonymous], 2005, CURR ANAESTH CRIT CA, DOI DOI 10.1016/J.CACC.2005.03.005

[2]

Healing of diabetic foot ulcers in L-arginine-treated patients [J].